Recent News

The latest news from the governments, medical industry and top online sources.

Management Board formally approves renewal of Executive Dire…

EMA’s Management Board has unanimously approved the renewal of the mandate of the Agency’s Executive Director Emer Cooke, extending her tenure until 30 April 2027. The Board’s decision follows the successful completion of the renewal process which was initiated by the European Commission earlier this year. The Commission has been formally notified of the Management […]

AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025

Topical TRPV1 antagonist shows promise in heat-induced neuropathic pain lzeCure Pharma has presented new clinical data on its lead pain candidate ACD440 at the NeuPSIG 2025 international pain conference. The presentation includes results from the phase 2 study in chronic peripheral neuropathic pain. ACD440 is a first-in-class TRPV1 antagonist developed as a topical gel for […]

EMA closed on 15 August for Assumption Day

The European Medicines Agency’s (EMA) office is closed from 18:00 on Thursday 14 August 2025 to 08:30 on Monday 18 August 2025. Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600. Please note that this is an emergency number and should only be used […]

Vedanta’s ulcerative colitis candidate misses phase 2 effica…

Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection Vedanta Biosciences has announced that VE202 failed to meet the primary endpoint in its phase 2 COLLECTiVE202 study for mild-to-moderate ulcerative colitis. The trial assessed endoscopic response at Week 8, but results showed no statistically significant difference between VE202 and placebo. Clinical […]

Meeting highlights from the Committee for Medicinal Products…

13 new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended 13 medicines for approval at its July 2025 meeting. The committee recommended granting a marketing authorisation for Aqneursa* (levacetylleucine), for the treatment of Niemann-Pick type C, a rare, progressive, fatal genetic disorder caused by mutations encoding lysosomal proteins that are essential for the […]

Akari Therapeutics advances research on novel PH1 payload fo…

Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in its antibody drug conjugates (ADCs), which may offer a new approach to treating cancers driven by oncogenic mutations. PH1 modulates RNA splicing to induce cancer cell death and activate the immune system. It generates neoantigens through mis-spliced […]

Strengthening supply chain of anti-D immunoglobulins

EMA and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), have issued recommendations to address vulnerabilities in the supply chain of anti-D immunoglobulins. These medicines are currently the only available treatment for the prevention of RhD immunisation during pregnancy. RhD immunisation happens when a pregnant person with RhD-negative blood […]

Neumifil shows promise in treating influenza with positive p…

Pneumagen’s intranasal antiviral demonstrates reduced infection Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced influenza infection and symptoms. The findings appear in the peer-reviewed journal Infectious Diseases and Therapy. Neumifil is a broad-spectrum, intranasal antiviral developed for the prevention and treatment of viral respiratory tract infections. Pneumagen’s […]

EMA Management Board: highlights of June 2025 meeting

Management Board meets the African Medicines Agency Governing Board The Management Board welcomed the African Medicines Agency (AMA) Governing Board and heads of African national agencies as observers in a first-of-its-kind meeting between the European and African regulatory network. The delegation was led by Dr Yossounon Chabi, Chair of the AMA Governing Board and Director-General […]

Bimekizumab shows lasting efficacy at EULAR 2025

Three-year data highlights inflammation control in psoriatic arthritis UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) in psoriatic arthritis and axial spondyloarthritis. The results, presented at EULAR 2025, show sustained inflammation control and significant long-term improvements in symptom relief and physical function. In psoriatic arthritis, 53.2% […]